Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

07741

Supelco

Everolimus

analytical standard

Synonym(e):

42-O-(2-Hydroxyethyl)-rapamycin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C53H83NO14
CAS-Nummer:
159351-69-6
Molekulargewicht:
958.22
MDL-Nummer:
MFCD00929329
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329748511

Qualität

analytical standard

Assay

≥95% (HPLC)

Haltbarkeit

limited shelf life, expiry date on the label

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

Anwendung(en)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

Lagertemp.

−20°C

SMILES String

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChIKey

HKVAMNSJSFKALM-GKUWKFKPSA-N

Angaben zum Gen

human ... FKBP1A(2280)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verpackung

Bottomless glass bottle. Contents are inside inserted fused cone.

Hinweis zur Analyse

Genauer Gehalt und Verfalldatum können dem jeder Packung beiliegenden Zertifikat entnommen werden.

Rechtliche Hinweise

CERTICAN is a registered trademark of Novartis AG

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Health hazardEnvironment
GHS08,GHS09

Signalwort

Warning

Gefahreneinstufungen

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

Zielorgane

Kidney,Testes

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number
BCBS2040V
BCBR8517V
BCBP8733V
BCBP1603V
BCBM2224V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 1

1 of 1

Palbociclib ≥98% (HPLC)

Sigma-Aldrich

PZ0383

Palbociclib

Inge Verbrugge et al.
Radiation research, 182(2), 219-229 (2014-06-25)
Radiotherapy is a successful treatment modality for localized cancer. Our group has been exploring radiotherapy in combination with immunotherapy (radioimmunotherapy) to enhance systemic antitumor responses. Previously, we have shown that when local radiotherapy was combined with monoclonal antibodies (mAbs) (that
Robert J Motzer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(25), 2765-2772 (2014-07-23)
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma. RECORD-3 used a crossover treatment
Atsushi Ohtsu et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3935-3943 (2013-09-18)
The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in
Simron Singh et al.
Neuroendocrinology, 106(3), 211-220 (2017-05-30)
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine
Joëlle Elias et al.
Heart (British Cardiac Society), 104(17), 1432-1438 (2018-02-22)
During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.